All News
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?
An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.
Read Article
Medication adherence is a problem
Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects).
This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw
Richard Conway RichardPAConway ( View Tweet)
Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose of PCV13 at day 0 and day 7 followed by single dose of PPV23 at month 5 significantly improves antibody responses (2 in figure) @RheumNow #ACR22 Abstr#L016 https://t.co/qKqgvv7ZwI https://t.co/UHCuZNSF54
Richard Conway RichardPAConway ( View Tweet)
I see that despite the condensing of the #ACR22 to 3 days, people are keeping the tradition of leaving at the start of the last day despite it now being a full day. Personally don't think the 3 day meeting has worked, its too packed. @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Promises to be a fantastic session!
🌟Delighted PMR is getting the attention it deserves 🌟
2pm GMT/ 9am EST
#ACR22 @RheumNow
@SattuiSEMD @EBRheum @drceowen https://t.co/ShRTS1DLXO
Patricia Harkins DrTrishHarkins ( View Tweet)
"Anterior uveitis is often a symptom and not just a diagnosis." Dr. J Kolfenbach reminds us to remember to look deeper for underlying causes during his #ACR22 Secrets and Pearls lecture. @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Abst0324 #ACR22
How close are we to measuring Interferon Signature in clinical practice?
NCounter and BioFire assays studied - correlated well we each other
Genes: IFI27, IFI44L, IFIT1, RSAD2
SLE higher than RA or FMS, but does not correlate with SLE activity
@RheumNow https://t.co/izpFtj9Pcd
Eric Dein ericdeinmd ( View Tweet)
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
Eric Dein ericdeinmd ( View Tweet)
$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v
TheDaoIndex KDAO2011 ( View Tweet)
"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD
Dr. Rachel Tate uptoTate ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Lab Domains:
LAC not always feasible to recheck
aCL, aB2GP IgG higher risk, higher titers (>40U)
@RheumNow https://t.co/rcQaqrtDN5
Eric Dein ericdeinmd ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Obstetric domain redefined
Added:
⭐️Cardiac thickening/vegetation
⭐️Thrombocytopenia
@Rheumnow https://t.co/Me2jrnvalU
Eric Dein ericdeinmd ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Novel Aspects
Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles
Microvasc - Suspected/Established
@RheumNow https://t.co/M8NWRSyH4p
Eric Dein ericdeinmd ( View Tweet)
Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb
Richard Conway RichardPAConway ( View Tweet)
Frailty in Vasculitis
Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence.
https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W
Links:
Dr. John Cush RheumNow ( View Tweet)
Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU
Richard Conway RichardPAConway ( View Tweet)
Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz
Richard Conway RichardPAConway ( View Tweet)
Arora @BichileT et al. PJP prophylaxis practice among nephrologists and rheumatologists @RheumNow #ACR22 Abstr#1282 https://t.co/3VyJR6k76U https://t.co/VM5rnbmv9h
Richard Conway RichardPAConway ( View Tweet)
